Skip to main content

Table 4 Secondary outcomes

From: In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review

Characteristic

rFSH

hMG-HP

p-value

All Patients

Mean (SD)oocyte yield (number of oocytes retrieved) (All patients)

10.80 (6.02)

9.77 (5.53)

<0.01

10.53 (5.91)

   (≤35 years)

11.21 (6.11)

10.28 (5.6)

<0.01

10.98 (6.0)

   (≥36 years)

9.93 (5.74)

8.83 (5.27)

<0.01

9.62 (5.63)

Mean (SD) mature oocyte yield (All Patients)

8.58 (5.27)

7.72 (4.59)

<0.01

8.35 (5.11)

   (≤35 years)

8.80 (5.35)

8.08 (4.66)

<0.01

8.62 (5.19)

   (≥36 years)

8.09 (5.06)

7.08 (4.38)

<0.01

7.80 (4.9)

Number of embryos transferred (fresh)

1.91 (0.86)

1.96 (0.68)

<0.01

1.93 (0.81)

   (≤35 years)

1.89 (0.84)

1.94 (0.63)

<0.01

1.91 (0.79)

   (≥36 years)

1.96 (0.89)

2.00 (0.76)

<0.01

1.97 (0.85)

Mean number of oocytes/embryos frozen per cycle All patients

2.14 (3.29)

1.7 (2.8)

<0.01

2.02 (3.18)

   (≤35 years)

2.32 (3.4)

1.8 (2.85)

<0.01

2.18 (3.27)

   (≥36 years)

1.77 (3.03)

1.51 (2.68)

<0.01

1.70 (2.94)

Number of embryos thawed and used in FET** cycles† (All patients)

0.74 (0.97)

0.67 (0.93)

<0.01

0.74 (0.97)

   (≤35 years)

0.67 (0.95)

0.57 (0.9)

<0.01

0.67 (0.94)

   (≥36 years)

0.91 (1.03)

0.87 (0.99)

<0.01

0.91 (1.02)

  1. * Statistical significance for outcomes assessed via Wilcoxon two sample test and two sample T-test
  2. † Statistical significance assessed via the two sample T-test only
  3. ** FET - Frozen Embryo Transfer